Taken together, the findings described above indicate that PPARδ agonists show promise as potential therapeutic agents for a variety of CNS pathologies, including stroke, MS, AD, PD, radiation-induced brain injury, and SCI. The gene discussed is PPARD; the disease is Stroke.